360A |
| カタログ番号GC15389 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 794458-56-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Description: IC50 Value: N/A 360A is a 2,6-pyridine-dicarboxamide derivative displaying strong affinity and selectivity for G-quadruplex structures and selective telomerase inhibition in vitro assays. 360A is a G-quadruplex ligand, which can influence the consequence of G-quadruplex formation and/or stabilization. in vitro: We found a S-phase accumulation in ATM-proficient, but not in ATM-deficient EBV-lymphocytes treated with 360A before induction of cell death. However, ATM status did not modify cell cycle distribution in 360A-treated SV40-fibroblasts and HeLa cells compared to DMSO treated controls [1]. DNA-PKcs-dependent NHEJ was responsible for sister telomere fusions as a direct consequence of G-quadruplex formation and/or stabilization induced by 360A on parental telomere G strands. NHEJ and HR activation at telomeres altered mitotic progression in treated cells [2]. This compound was shown to display a potent affinity and selectivity for telomeric G-quadruplex DNA over duplex DNA and to induce delayed growth inhibition in HT1080 tumor cell line [3]. in vivo: N/A Clinical trial: N/A
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *